Our technology combines a proprietary biological assay and machine learning algorithms that, together, enable rapid, high-resolution snapshots of cellular dynamics following drug treatment. These snapshots are then analyzed to reveal the biological networks that determine a drug’s function and guide therapeutic development.
We are comprised of a talented, diversely-skilled team, working together towards the mission of helping bring new therapies to patients with epigenetically-driven diseases.
We are comprised of a talented, diversely-skilled team, working together towards the mission of helping bring new therapies to patients with epigenetically-driven diseases.
Location: United States, Colorado, Boulder
Employees: 1-10
Total raised: $20.2M
Founded date: 2017
Investors 3
| Date | Name | Website |
| - | Fifty Year... | fiftyyears... |
| 21.07.2020 | Y Combinat... | ycombinato... |
| - | Tencent | tenx.tc |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.09.2022 | Series A | $17M | - |
| 17.01.2020 | Seed | $3.2M | - |
Mentions in press and media 5
| Date | Title | Description |
| 29.05.2024 | Slone Partners Places Kevin Eastwood as Chief Business Officer at Arpeggio Biosciences | Slone Partners Places Kevin Eastwood as Chief Business Officer at Arpeggio Biosciences Industry veteran brings more than 25 years of experience in senior leadership roles SOUTH RIDING, Va., May 29, 2024 /PRNewswire-PRWeb/ -- Slone Partners,... |
| 05.05.2024 | Business | Boulder life-sciences leaders: Pfizer’s exit means opportunity | Lefkoff listed “six identifiable spinoffs” since Pfizer bought Array, four of which are publicly traded companies. They’re all doing very well. “That’s what you want to see in an ecosystem like ours,” he said. “Nobody leaves, nobody’s freak... |
| 07.09.2022 | Arpeggio Biosciences Raises $17M in Series A Funding | Arpeggio Biosciences, a Boulder, CO-based preclinical therapeutics company whose technology targets transcriptional dysregulation in disease, raised $17m in Series A funding. The round, which follows a $3.2m seed round completed in 2020, wa... |
| 07.09.2022 | Arpeggio Biosciences rakes in $17M to measure the transcriptome | How can drug developers design therapies around cellular networks rather than a single target? That is the question Arpeggio Biosciences is seeking to answer — and with a new influx of funds. The Boulder, Colorado-based startup announced th... |
| 15.01.2020 | Arpeggio Bio Secures USD 3.2M in Seed Funding | Arpeggio Bio , a Boulder, Colo.-based preclinical company whose technology provides a mechanistic understanding of how drugs work, closed a $3.2m seed financing round. Backers included Khosla Ventures, FundersClub, Fifty Years, TechU, and Y... |